Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

DDR1-2/VEGFR2-3/PDGFRalpha-beta inhibitor ICP-033

An orally bioavailable inhibitor of multiple receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, DDR1-2/VEGFR2-3/PDGFRalpha-beta inhibitor ICP-033 selectively targets, binds to and inhibits the activity of numerous RTKs including discoid domain receptor type 1 (DDR1) and 2 (DDR2), vascular endothelial growth factor receptors type 2 (VEGFR2) and 3 (VEGFR3) and platelet-derived growth factor receptor alpha (PDGFRa) and beta (PDGFRb). By inhibiting multiple RTKs located in endothelial cells, pericytes and stroma, ICP-033 may be able to inhibit angiogenesis and tumor cell invasion, normalize abnormal blood vessels, and reverse the immunosuppressive state of the tumor microenvironment (TME). This may halt tumor cell proliferation in susceptible tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:RTK inhibitor ICP-033
Code name:ICP 033
ICP-033
ICP033
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search